TITLE

Cost of illness of inflammatory single centre retrospective study

AUTHOR(S)
Bassi, A.; Dodd, S.; Williamson, P.; Bodger, K.
PUB. DATE
October 2004
SOURCE
Gut;Oct2004, Vol. 53 Issue 10, p1471
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: The potentially high costs of care associated with inflammatory bowel disease (IBD) are recognised but we have little knowledge of the scale, profile, or determinants of these costs in the UK. This study aimed to describe costs of illness for a group of IBD patients and determine factors associated with increased healthcare costs. Setting: A university hospital serving a target population of approximately 330 000. Patients and Methods: A six month cohort of IBD patients receiving any form of secondary care was identified, comprising 307 cases of ulcerative (or indeterminate) colitis and 172 cases of Crohn's disease. Demographic and clinical data were abstracted from clinical records and individual resource use was itemised for all attributable costs (including extraintestinal manifestations). Item costs were derived from national and local sources. Cost data were expressed as mean six month costs per patient (with 95% confidence interval (CI)) obtained using non-parametric bootstrapping. Determinants of cost were analysed using generalised linear regression modelling. A postal survey of patients was undertaken to examine indirect costs, out of pocket expenses, and primary care visits. Results:Inpatient services (medical and/or surgical) were required by 67 patients (14%) but accounted for 49% of total secondary care costs. Drug costs accounted for less than a quarter of total costs. Individual patient costs ranged from 73 to 33,254 UK £ per six months. Mean (95% CI) six month costs per patient were 1256 UK £ ( 988 £, 1721 £) for colitis and 1652 UK £ (1221 £, 2239 £) for Crohn's disease. Hospitalisation, disease severity grade, and disease extent correlated positively with cost of illness but costs were independent of age or sex. Compared with quiescent cases of IBD, disease relapse was associated with a 2-3-fold increase in costs for non-hospitalised cases and a 20-fold increase in costs for hospitalised cases. Survey data suggested average six month costs were < 30 UK £ per patient for primary care visits (both diseases) and median loss of earnings were 239 UK £ for colitis and 299 UK £ for Crohn's disease. Conclusions:This study represents the first detailed characterisation of the scale and determinants of costs of illness for IBD in a British hospital. Hospitalisation affected a minority of sufferers but accounted for half of the total direct costs falling on the healthcare system.
ACCESSION #
14674393

 

Related Articles

  • Editorial: Administrative Database Studies in IBD: A Cautionary Tale. Kaplan, Gilaad G. // American Journal of Gastroenterology;Aug2010, Vol. 105 Issue 8, p1808 

    The inflammatory bowel diseases (IBDs) have been extensively studied with administrative databases. Ananthakrishnan et al. (this issue) used an administrative database to develop a risk score that predicted disease severity in hospitalized Crohn's disease patients. To understand the implication...

  • Natalizumab reduces hospitalisation rate in patients with CD.  // PharmacoEconomics & Outcomes News;11/15/2008, Issue 566, p9 

    The article discusses research being done on the impact of natalizumab on hospitalization rate in patients with Crohn's disease. It references a study by B. E. et al, presented at the 16th United European Gastroenterology Week. Researchers from the U.S. and Great Britain randomised patients to a...

  • How to recognize and treat IBD. Lichtenstein, Gary R.; Hanauer, Stephen B.; Peppercorn, Mark A. // Patient Care for the Nurse Practitioner;Dec2005, Vol. 8 Issue 12, p1 

    The article focuses on recognizing, diagnosing and managing of inflammatory bowel disease (IBD). IBD remained as an underdiagnosed condition in the primary care setting. The symptoms overlap with functional gut disorders, such as irritable bowel syndrome or food or lactose intolerance. The two...

  • Costs of Inflammatory Bowel Disease in Germany. Stark, Renee; König, Hans-Helmut; Leidl, Reiner // PharmacoEconomics;2006, Vol. 24 Issue 8, p797 

    Introduction: Inflammatory bowel disease (IBD) is a chronic condition that Abstract afflicts young adults in their economically productive years. The goal of this study was to determine the costs of IBD in Germany from a societal perspective, using cost diaries. Methods: Members of the German...

  • Cost Effectiveness of Treatments for Inflammatory Bowel Disease. Bodger, Keith // PharmacoEconomics;2011, Vol. 29 Issue 5, p387 

    Traditionally, half of the direct costs associated with chronic inflammatory bowel diseases (IBD) [Crohn's disease (CD) and ulcerative colitis (UC)] have related to hospital inpatient treatment for a sub-group of more severely affected, often therapy-resistant individuals. The advent of...

  • Vitamin D Status in Veterans With Inflammatory Bowel Disease: Relationship to Health Care Costs and Services. Atia, Antwan; Murthy, Ravindra; Bailey, Beth A.; Manning, Todd; Garrett, Linda L.; Youssef, Dima; Peiris, Alan N. // Military Medicine;Jun2011, Vol. 176 Issue 6, p711 

    Vitamin D deficiency is a global pandemic associated with increased health care costs and could play a role in the pathogenesis and management of inflammatory bowel disease. This study examined vitamin D status in veterans with ulcerative colitis (UC) and Crohn's disease (CD) and assessed its...

  • Is infliximab good value for money in IBD?  // PharmacoEconomics & Outcomes News;7/1/2013, Issue 682, p7 

    The article discusses research on infliximab as maintenance treatment (MT) for inflammatory bowel disease. It references the studies "Cost-Effectiveness (CE) of Infliximab Scheduled MT for the Management of Patients With Moderate-to-Severe Ulcerative Colitis," by A. A. Tahami Monfared, et al,...

  • Inflammatory bowel disease: not all costs are equal in Germany.  // PharmacoEconomics & Outcomes News;9/6/2006, Issue 511, p5 

    The article discusses research being done on the costs of inflammatory bowel disease in Germany. It references a study by R. Stark et al published in a 2006 issue of "PharmacoEconomics." The study indicates the cost differences between Crohn's disease (CD) and ulcerative colitis. Factors...

  • Infliximab reduces subsequent costs in Crohn's disease.  // PharmacoEconomics & Outcomes News;5/2/2009, Issue 577, p5 

    The article focuses on the results of a study on the decrease in subsequent in inflammatory bowel disease-related costs in patients with Crohn's disease due to the use of infliximab presented in the 2009 Annual Meeting of the British Society of Gastroenterology. The study included information on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics